Physician profile
Cleatious David Smith
NPI 1871546515
$4,499.82
in general payments reported to CMS, 2019-2025
29 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $440 · 2021: $779 · 2022: $787 · 2023: $600 · 2024: $1,011 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,265.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $498.37 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $485.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $457.21 | 2020-2025 | Vraylar, Qulipta, Linzess |
| Janssen Pharmaceuticals, INC | $304.92 | 2019-2022 | |
| Dexcom, INC. | $301.19 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $188.44 | 2019-2025 | |
| Lilly USA, LLC | $147.88 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $132.00 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $115.33 | 2019-2022 | |
| Allergan, INC. | $81.83 | 2019-2020 | |
| Esperion Therapeutics, INC. | $66.19 | 2021-2024 | Nexletol |
| Mannkind Corporation | $59.40 | 2022 | |
| Sunovion Pharmaceuticals INC. | $58.31 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $41.67 | 2023-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.43 | 2020-2021 | |
| Amgen INC. | $38.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.13 | 2024-2025 | Trintellix |
| Astellas Pharma US INC | $23.16 | 2025 | Veozah |
| Jazz Pharmaceuticals INC. | $23.08 | 2021 | |
| Cmp Pharma, INC. | $19.25 | 2020 | |
| Corcept Therapeutics | $19.16 | 2024 | Korlym |
| Azurity Pharmaceuticals, INC. | $16.70 | 2024 | |
| Sumitomo Pharma America, INC. | $16.30 | 2024 | Gemtesa |
| Eisai INC. | $15.72 | 2022 | |
| Ardelyx, INC. | $14.71 | 2025 | Ibsrela |
| Avanir Pharmaceuticals, INC. | $12.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.51 | 2021 | |
| Merck Sharp & Dohme LLC | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cleatious Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.